

# PRE-HOSPITAL MANAGEMENT OF DECOMPRESSION ILLNESS: EXPERT REVIEW OF KEY PRINCIPLES AND CONTROVERSIES

Diving Hyperb Med. 2018 Mar 31;48(1):45-55

Pierre Lafère, MD-PhD




Elke reproductie, geheel of gedeeltelijk, van deze presentatie mag slechts gebeuren met voorafgaandelijk akkoord van de auteur.

Toute reproduction, partielle ou intégrale, de cet exposé et de ces notes ne peut se faire qu'avec l'accord préalable de l'auteur.

2

- No personal or financial interest to declare.
- No financial support from an industry source at the current presentation.
- Affiliated with DAN Europe as DMO for the DAN Europe Emergency Hotline

## Conflict of interest disclosure statement



Corticoids Usefull? UHMS: Hell No...  
ECHM: Maybe...

### Prevention and Treatment of Decompression Sickness and Arterial Gas Embolism

### Adjunctive Therapy – Medications

Low molecular weight heparin for paraplegia – enoxaparin 30 mg q12h or  
or dalteparin 5000 IU SQ q24h  
No aspirin  
No corticosteroids  
No lidocaine

repeat of initial success.<sup>12,13,14</sup> Lidocaine is usually reserved for serious neurological cases with features typical of arterial gas embolism. High-dose steroids worsen outcome in animals<sup>15</sup> and are not recommended in people.<sup>106</sup>

acute spinal cord injury have recently been discussed.<sup>29</sup> A review of the use of high-dose methylprednisolone in DCI has resulted in a recommendation that corticosteroids not be used in DCI.<sup>21</sup>

Moon RE, Ed. *Adjunctive Therapy for Decompression Illness*. Kensington, MD: Undersea and Hyperbaric Medical Society; 2003.

## Preliminary remarks

Corticoids Usefull? UHMS: **Hell No...**  
ECHM: **Maybe...**

## HOWEVER...

function. There are currently no published data providing unequivocal support for the use of corticosteroids in DCI, although the evidence to the contrary may only be due to the lack of a trial using an appropriate dose. Therefore, the issue of efficacy of these compounds in this disease remains an open question.

Moon, 1998. SPUMS; 28 (3): 144-9

Whether corticosteroids should be administered routinely to divers with neurological DCI therefore remains undecided. On the basis of the information from studies in spinal cord trauma, if corticosteroids are administered they should probably be given early, preferably within the first 8 hours after symptom onset.

Moon, 2000, SPUMS; 30 (2): 99-112

## Preliminary remarks

Has Science Gone Too Far?  
IS THIS IMAGE REAL OR FAKE?

REAL FAKE





Preliminary remarks

Are you drunk?

☐ Yes ☐ No

- Almost no evidence or of low quality
- Mainly expert opinion
- Other fields potentially useful?
- Physiopathology makes logical sense

Preliminary remarks



Authors	DCI Type	# patients	TTR cut off	Association
Reura 1964	Type I & II	888	<3 hours (n=514) >3 hours (n=172) >4 hours (n=93) >12 hours (n=70) >24 hours (n=21) >48 hours (n=18)	Yes in severe cases
Blair 1982	Type I & II	50	>12 hours (n=50) >24 hours (n=20)	Yes
Van Hult 1980	Type I & II CAGE	123	<12 hours (n=34) >12 hours (n=75) >24 hours (n=14)	Yes
Neun 1993	Type I & II	1,339	Unknown	No
Bell 1993	Type II Spinal cord	49	<12 hours (n=1) >12 hours (n=48) >24 hours (n=28)	Yes in severe cases
Wassenaar 1996	Type II Cerebral & Spinal cord	96	Unknown	No
Uusala 1997	Type I & II	465	<3 hours (n=112) >3 hours (n=104) >4 hours (n=48) >12 hours (n=43) >24 hours (n=69)	No
Blair 2007	Type II	390	Unknown	Yes in severe cases
Georg 2010	Type II Isolated	99	<6 hours (n=7) >6 hours (n=15)	Yes
Georg 2010	Type II Spinal cord	63	<6 hours (n=13) >6 hours (n=7)	No
Blatteau 2011	Type II Spinal cord	278	<6 hours (n=63) >6 hours (n=180) >12 hours (n=55) >24 hours (n=24) >36 hours (n=19)	No
Yu 2012	Type I & II Mild to severe	1,778	<6 hours (n=1,602) >6 hours (n=176) >12 hours (n=139)	Yes
Wahlbauer 2013	Type II Mild to moderate	28	>12 hours (n=13)	No
Lee 2015	Type I & II CAGE	195	>24 hours (n=90)	Yes
Hickman 2015	Type I & II	100	<48 hours (n=76)	No

Is TTR delay relevant in DCS?

U.S.N. Experimental Diving 1980 - 1989					
Time to Resolution			Complete Recovery		
	# cases	During Compression	≤10 minutes at depth	First Treatment	Eventually
N <sub>2</sub> -O <sub>2</sub>	91	26	36	88 (97%)	91
He-O <sub>2</sub>	75	34	19	73 (97%)	75
Total	166	64	55	161 (97%)	166

"little or no delay between symptom occurrence and treatment"

Thalman et al. 45<sup>th</sup> UHMS Workshop 1996

Short Delay to Recompression

Table 2 Analysis of clinical outcome at 1 month in divers with spinal cord DCS according to diving information, clinical characteristics, and treatment procedures					
Variables	Full recovery	Sequelae	Univariate analysis P-value	OR (95% CI)	Multivariate analysis P-value
Total (n = 276)	117	25			
Age (years)					
<42	117	25	0.003	2.5 (1.4-4.4)	0.042
>42	69	25			1.04 (1-1.07)
Dive time (min)					
<30	103	39			
>30	103	34	0.71	NA	
Depth (meters of sea water)					
<30	100	26			
>30	96	28	0.007	3.2 (1.3-3.8)	0.031
Inadequate decompression					
No	150	54			
Yes	56	39	0.97	NA	
Repetitive dive					
No	158	60			
Yes	48	13	0.417	NA	
Delay onset of symptoms (min)					
<30	53	8			
>30	153	65	0.014	2.8 (1.3-6)	0.067
Recompression delay (h)					
<3	94	30			
>3	69	13	0.7	0.7 (0.3-1.6)	0.191
>6	53	30	0.028	3.8 (1.3-11)	0.191

Longer Delay to Recompression

Best outcomes after recompression are likely to be obtained by immediate recompression.	
Green et al. Undersea Biomed Res. 1989; 16:465-70	
Thalman et al. Proceeding of the 45 <sup>th</sup> UHMS Workshop. 1996; 75-95	
Blatteau et al. DHM. 2011; 41:129-34	

Delay prior to recompression is unlikely to be associated with any worsening of long term outcome in case of mild symptoms.

Mitchell et al. DAN Workshop Proceeding. 2005; 239p

Limited evidence that delays longer than 6 hours result in slower or less complete recovery in case of severe symptoms.

Blatteau et al. Neuro Crit Care. 2011; 15:120-7

Is TTR delay relevant in DCS?


Best outcomes after recompression are likely to be obtained by immediate recompression.	
Green et al. Undersea Biomed Res. 1989; 16:465-70	
Thalman et al. Proceeding of the 45 <sup>th</sup> UHMS Workshop. 1996; 75-95	
Blatteau et al. DHM. 2011; 41:129-34	

If needed/mandatory, therapeutic recompression has to occur within 6 hours of symptoms onset

Limited evidence that delays longer than 6 hours result in slower or less complete recovery in case of severe symptoms.

Blatteau et al. Neuro Crit Care. 2011; 15:120-7

Is TTR delay relevant in DCS?





Severity Score	After first HBO			Final Outcome		
	Complete resolution	Mild residual	Severe residual	Complete resolution*	Mild residual	Severe residual
Received First-aid & HBO						
<7 (n=9)	8	1	0	8	1	0
7-13 (n=8)	2	4	2	4	2	2
>13 (n=16)	2	6	8	1	9	6
Received First-aid						
<7 (n=31)	-	-	-	25	6	0
7-13 (n=2)	-	-	-	1	1	0
Not seeking help						
<7 (n=30)	-	-	-	29	1	0
7-13 (n=4)	-	-	-	2	2	0
<b>Total</b>	<b>12</b>	<b>11</b>	<b>10</b>	<b>84 (73.7%)</b>	<b>22 (19.3%)</b>	<b>8 (7%)</b>

Manol et al. Diving Hyperb Med. 2019;49(2): 96-106

A physician trained in diving medicine should advise whether hyperbaric chamber treatment is required and its urgency. Laypersons and even physicians without diving medicine training are generally insufficiently trained to give such advice

MEDSUBHYP, SUHMS, GtÜM recommendation



Administration of oxygen is not considered a standard first aid skill.

AHA 2015 recommendation

This recommendation suffers one major exception, which is the relief of decompression sickness

AHA 2015 recommendation

Oxygen in First-Aid





Table 5  
Final outcome and applied treatment among DCI cases (n = 114); mild residual symptoms are mild paresthesia, weakness, residual pain or some impairment of daily activities. Severe residual symptoms are difficulty walking, paralysis, uncompensated vertigo, or speech disorders. \*14 divers (12) with a severity score < 7, between 7-13 had a spontaneous recovery with full resolution without any treatment, although they activated the emergency response system.

	Severity score	After first HBO <sup>2</sup>			Final outcome		
		Complete resolution	Mild residual	Severe residual	Complete resolution*	Mild residual	Severe residual
Received first-aid and HBO <sup>2</sup>	<7 (n = 9)	8	1	0	8	1	0
	7-13 (n = 8)	2	4	2	4	2	2
	>13 (n = 16)	2	6	8	1	9	6
	(n = 33)	12	11	10	13	12	8
Received first-aid	<7 (n = 31)	—	—	—	25	6	0
	7-13 (n = 2)	—	—	—	1	1	0
Not seeking help	<7 (n = 30)	—	—	—	29	1	0
	7-13 (n = 4)	—	—	—	2	2	0
Total					84 (74%)	22 (19%)	8 (7%)

### FAO<sub>2</sub> among Humans

TABLE 2  
OXYGEN FIRST AID AND HYPERBARIC TREATMENT RESULTS (percentage)<sup>a</sup>


Surface Oxygen	Complete recovery	Partial/temporary	None	Residual symptoms	MARRONI'S EUROPEAN DAN DATA 1989-1993	
					Oxygen	No Oxygen
No	2	38	60	47	119	59
Yes	13	54	32	42	83	41

Symptoms before treatment:  
Resolved: 14 (12), Improved: 66 (55), Unchanged: 39 (33)  
Symptoms after treatment:  
Full resolution: 114 (94), Residual symptoms: 4 (4)


Lippmann, SPUMS, 2003, 33: 192-198  
Marroni, Handbook on Hyperbaric Medicine, 1996; 265-276

Improved outcome?  
Effect of surface O<sub>2</sub> alone?

### FAO<sub>2</sub> among Humans




### FAO<sub>2</sub> among Humans









### FAO<sub>2</sub> among Humans




### Best FiO<sub>2</sub>?



### Best FiO<sub>2</sub>?





DW5

Oral Hydration is recommended but should be avoided if the patient is not fully conscious.

Fluids should be non-carbonated, non caffeinated, non alcoholic and ideally isotonic. (drinking water ok)

If suitably qualified and skilled responders are present, intravascular rehydration with non-glucose containing isotonic crystalloid is preferred.

If casualty breathing place in recovery position



The 'how' position

More stable position

Positioning the victim

Human evidence of enhanced inert gas washout in horizontal subjects

*In vivo* evidence of cephalad bubble distribution if upright

*In vivo* evidence that head down position is harmful in DCI

Positioning the victim

- Emphasized in the late 60's and 70's
- Place in First-aid = ?
- Mostly based on physiopathology
  - IV Pentoxifylline + Nicergoline
  - Aspirin
  - Lidocaine
  - Corticosteroids
- Limited success

Adjunctive therapies

- Emphasized in the late 60's and 70's
- Place in First-aid = ?
- Mostly based on physiopathology
  - IV Pentoxifylline + Nicergoline
  - Aspirin
  - Lidocaine
  - Corticosteroids
- Limited success

Adjunctive therapies

**No possible recommendation based on evidence  
Only expert opinion available**



- Double-blind prospective RCT
- 20mg tenoxicam daily (n=90) vs placebo (n=90)
- No NSAID related complications in tenoxicam group

Outcome	Placebo	Tenoxicam	P value (95% CI)
Health status at discharge >1	25 (30%)	31 (37%)	0.41 (21% to ~7%)
Health status at 4-6 weeks >1	16 (20%)	14 (17%)	0.58 (9% to ~20%)
Median treatments required to discharge (range)	3 (1 - 8)	2 (1 - 6)	0.01 (0 to 1)
Subjects requiring more than 2 treatments	53 (61%)	35 (40%)	0.01 (6% to 34%)

Bennett et al. UHM 2003;30(3):195-205.

## NSAID & DCS



### Fluoxetine Protection in Decompression Sickness in Mice is Enhanced by Blocking TREK-1 Potassium Channel with the "spadin" Antidepressant

Nicolas Vallet<sup>1</sup>, Kati Landrock<sup>1,2</sup>, Sébastien De Maistre<sup>1</sup>, Pierre Roger<sup>1</sup>, Jean-Marc L. Marc Borsotto<sup>1</sup>, Catherine Heuchaux<sup>1</sup>, Jacques Abramo<sup>1,2,3</sup>, Jean-Jacques Riso<sup>1</sup> and Jean-Eric Blatteau<sup>1</sup>

### Thirty-five Day Fluoxetine Treatment Limits Sensory-Motor Deficit and Biochemical Disorders in a Rat Model of Decompression Sickness

Caroline Cornard<sup>1</sup>, Sébastien De Maistre<sup>1</sup>, Jacques H. Abramo<sup>1,2,3</sup>, Laurent Chapuis<sup>1</sup>, Jean-Eric Blatteau<sup>1</sup>, Jean-Jacques Riso<sup>1</sup> and Nicolas Vallet<sup>1,2,3</sup>

<sup>1</sup>Equipe Neurologie de Recherche, Laboratoire de Neurologie, Département d'Environnement Opérationnel, Centre de Recherche en Neurologie, Université de la Méditerranée, Marseille, France; <sup>2</sup>Equipe Neurologie de Recherche, Laboratoire de Neurologie, Département d'Environnement Opérationnel, Centre de Recherche en Neurologie, Université de la Méditerranée, Marseille, France; <sup>3</sup>Equipe Neurologie de Recherche, Laboratoire de Neurologie, Département d'Environnement Opérationnel, Centre de Recherche en Neurologie, Université de la Méditerranée, Marseille, France

## Future Trend?

Treatment with NSAID is appropriate if no contraindications

No evidence to support/refute the use of other agents:  
Corticosteroids, pentoxifylline, aspirin, lidocaine, nicergoline,...



## Flight evacuation




Fig. 1. Venous gas emboli evolution during flight in six divers. Difference in bubble grades between baseline (control 1 and control 2) - equal to zero and the mean flight 30, 60, and 90 min after takeoff. No significant difference. \*P < 0.05; \*\*P < 0.01. Note: 6 of the 12 divers developed venous gas emboli during flight; these were the same subjects that developed bubbles every day after every dive.

Outgoing Flight: no bubble

Diving week:  
non-bubblers (n=16)  
occasional bubblers (n=10)  
consistent bubblers (n=6)

24 hours free-interval

Return Flight: no bubble pre-flight

Claioni et al. ASEM 2014;85(10):993-8

## Accurate recommendation?

- Is it worth the risk of drowning?
- No medically supervised demonstration of the efficacy of IWR
- Some evidence
  - Efficacy of short delay to recompression
  - Efficacy of shallow recompression
- Threshold delay for retrieval versus IWR?
- Training level for IWR?

## IWR Controversy






### Patent Foramen Ovale (PFO), Personality Traits, and Iterative Decompression Sickness. Retrospective Analysis of 209 Cases

Pierre Lafère<sup>1,2</sup>, Costantino Balestra<sup>3,4,5,6</sup>, Dirk Caers<sup>7</sup> and Peter Gerngross<sup>8,9</sup>

TABLE 1 | Long term outcomes of 209 divers with cerebral decompression sickness.

	1st DCS (n = 125)	2nd DCS (n = 79)	3rd DCS (n = 14)	p
Dives/year	40 ± 2.7 [5–168, median 34]	70 ± 8.1 [25–200, median 60]	74 ± 8.9 [20–125, median 77]	<0.0001
Treatment received	1 ± 0.07 USN TT6 [0–2, median 1] 7 ± 0.8 HBOT [0–20, median 6]	1 ± 0.14 USN TT6 [0–2, median 1] 11 ± 1.3 HBOT [4–18, median 10]	1 ± 0.17 USN TT6 [0–2, median 1] 8 ± 1 HBOT [2–12, median 8]	0.75 0.04
Outcome				
Complete resolution	73.6%	27.1%	0%	
Mild residual symptoms	19.2%	57.1%	85.7%	0.08
Severe residual symptoms	7.2%	16.7%	14.3%	
Resume diving	81.6%	84.3%	0%	NA
Delay to resume diving	4.2 ± 0.7 months [0.5–15, median 5]	3.5 ± 0.6 months [1–6, median 5.5]	NA	0.97

Mild residual symptoms are mild paresthesia, weakness, residual pain or some impairment of daily activities. Severe residual symptoms are difficulty walking, paralysis, uncompensated vertigo, or speech disorders. USN TT6 US Navy Treatment Table 6, i.e., 2.8 ATA, 100% oxygen for 285 min with air break. HBOT Hyperbaric oxygen session 2.5 ATA, 100% of oxygen for 70 min without air break. Data are presented as mean ± standard error or mean (SD).



## PRE-HOSPITAL MANAGEMENT OF DECOMPRESSION ILLNESS: EXPERT REVIEW OF KEY PRINCIPLES AND CONTROVERSIES

Diving Hyperb Med. 2018 Mar 31;48(1):45-55

Pierre Lafère, MD-PhD